What is Dogwood Therapeutics, Inc.'s (DWTX) StockRank?

MoatMap's StockRank for Dogwood Therapeutics, Inc. (DWTX) is 9/100, with a Strong Sell signal. This is a composite score combining Quality (34), Value (34), and Momentum (16) factor ranks across MoatMap's universe of 25,000+ stocks.

Does Dogwood Therapeutics, Inc. have an economic moat?

Dogwood Therapeutics, Inc. (DWTX) has a Quality factor score of 34/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Dogwood Therapeutics, Inc. a buy, hold, or sell?

MoatMap's current signal for Dogwood Therapeutics, Inc. (DWTX) is Strong Sell, based on a StockRank of 9/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.

What sector is Dogwood Therapeutics, Inc. in?

Dogwood Therapeutics, Inc. (DWTX) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

DWTX

Strong SellSinker

Dogwood Therapeutics, Inc. · Healthcare · United States · $90M · Avg Vol: $126K/d

StockRank

Get insider-trade alerts

P/E (TTM)

1.2x

ROE

-47.8%

D/E

0.0x

Dividend %

—

COMPANY DESCRIPTION

Dogwood Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel antiviral therapies to treat chronic diseases, including fibromyalgia and long-COVID. The company's competitive position is anchored by its proprietary combination therapies targeting herpes simplex virus type 1 (HSV-1) as a potential driver of chronic illness. It operates as a niche clinical developer addressing high-barrier, underserved patient populations.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR	TTM
Revenue	0	0	0	0	—	—
EPS	-0.61	-0.16	-0.50	-7.13	—	1.89
Shares	33.6M	33.6M	33.6M	29.7M	-11.6%	34.0M
Debt	—	0	15.6M	0.2M	-99.0%	0.1M
Equity	7.3M	3.8M	64.3M	74.9M	117.0%	—
Op CF	-11.5M	-4.9M	-8.8M	-15.6M	—	-15.1M
Inv CF	—	0	3.8M	0	—	—
Fin CF	4.5M	1.2M	16.7M	7.3M	—	—

Loading 1Y...

PRICE (1Y)+19.0%

SMA 50SMA 200

$1.88

RSI (14)

38.2

52W High

$9.50

From 52W High

0.2%

SCORE BREAKDOWN

Quality

ROIC

-32.1%23.4

ROE

-47.8%19.1

GP/Assets

—N/A

Op. Margin

0.0%38.1

FCF/Assets

-19.1%21.7

Piotroski

321.9

Int. Cover

—N/A

D/E Ratio

0.00x92.5

Current Ratio

3.89x64.7

Value

P/E (TTM)

1.2x25.0

EV/EBITDA

-2.4x25.0

P/FCF

—N/A

P/B

1.1x82.6

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

20%3.3

RS 6M

-46%15.6

SMA 50/200

0.70x7.9

EPS Rev 4W

0.0%34.4

EPS Rev 12W

0.0%41.6

EPS Improve

-437%1.1

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$90M

P/E (Forward)

-0.4x

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of DWTX are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
DWTX	Dogwood Therapeutics, Inc.(you)	$90M	9	Strong Sell
KLRS	Kalaris Therapeutics, Inc.	$96M	7	Strong Sell
VRCA	Verrica Pharmaceuticals Inc.	$98M	7	Strong Sell
MAIA	MAIA Biotechnology, Inc.	$81M	11	Strong Sell
COYA	Coya Therapeutics, Inc.	$108M	10	Strong Sell
TENX	Tenax Therapeutics, Inc.	$80M	12	Strong Sell
CGTX	Cognition Therapeutics, Inc.	$97M	13	Strong Sell
GANX	Gain Therapeutics, Inc.	$77M	7	Strong Sell
ALDX	Aldeyra Therapeutics, Inc.	$90M	4	Strong Sell
CING	Cingulate Inc.	$77M	6	Strong Sell

Peer medians: ROE -30.2% · P/E 27.1x · Gross margin 58.3%

Dogwood Therapeutics, Inc. (DWTX): Stock Score Summary

Dogwood Therapeutics, Inc. (DWTX) has a MoatMap StockRank of 9/100 based on Quality (34/100), Value (34/100), and Momentum (16/100) factor scores. The current signal is STRONG SELL.

Key Financial Metrics

Price	$1.88
Market Cap	$90M
P/E (TTM)	1.21
P/E (Forward)	-0.36
Price/Book	1.13
Return on Equity	-47.8%
Return on Invested Capital	-32.1%
Debt/Equity	0.00x
Gross Margin	0.0%
Operating Margin	0.0%
Free Cash Flow	$-17M

Dogwood Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Dogwood Therapeutics, Inc.’s (DWTX) StockRank?: MoatMap’s StockRank for Dogwood Therapeutics, Inc. (DWTX) is 9/100, with a Strong Sell signal. It is a composite of Quality (34), Value (34), and Momentum (16) factor ranks across MoatMap’s universe of 25,000+ stocks.
Does Dogwood Therapeutics, Inc. have an economic moat?: Dogwood Therapeutics, Inc. (DWTX) has a Quality factor score of 34/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Dogwood Therapeutics, Inc. a buy, hold, or sell?: MoatMap’s current signal for Dogwood Therapeutics, Inc. (DWTX) is Strong Sell, based on a StockRank of 9/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is Dogwood Therapeutics, Inc. in?: Dogwood Therapeutics, Inc. (DWTX) operates in the Healthcare sector, specifically the Biotechnology industry (United States).